Condition

SARS-CoV-2 clinical trials and research

• 10Clinical trials
• 432NIH research projects
• 11Countries

Newest SARS-CoV-2 clinical trials

All recruiting trials (10)

• Vaccine formulations containing mRNA-1273 and mRNA-1283 to see if they boost immunity and remain safe

  This study tests whether two mRNA vaccines that target SARS-CoV-2 can safely generate an immune response in older adults and people with risk factors.

  Recruiting at 5 sites Phase 4 ModernaTX, Inc. · Overland Park, Kansas and 4 other locations · NCT07863635

• Vaccine study to test mRNA-1283 in children and infants

  A vaccine study will test two dose levels of mRNA-1283 in kids from 6 months to under 12 years to see which dose works best, using mRNA-1273 as a comparison.

  Recruiting at 12 sites Phase 2 ModernaTX, Inc. · Ontario, California and 30 other locations · NCT07808697

• Secutrelvir for high-risk COVID-19 patients who are not in hospital

  This study tests whether secutrelvir can help nonhospitalized teens and adults with COVID-19 who are at high risk of getting worse.

  Recruiting at 38 sites Phase 3 Shionogi Inc. · Coral Gables, Florida and 50 other locations · NCT07743580

• Kisspeptin to measure GnRH neuron function in people with and without post-COVID-19 syndrome

  We will give one intravenous kisspeptin dose and take frequent blood samples to see if people with post-COVID-19 syndrome have different GnRH/LH hormone responses than people who had COVID but did not develop long COVID.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT07224490

• Immunotherapy for treating SARS-CoV-2 and liver tumors

  This study is testing new immune treatments to see if they can help fight both COVID-19 and liver tumors.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06914635

• Evaluating a new treatment to prevent severe COVID-19 complications

  This study is testing a new treatment to see if it can help hospitalized COVID-19 patients avoid severe complications caused by inflammation.

  Recruiting at 3 sites Phase 1/2 Peaches Biotech · Alcalá de Henares, Madrid and 2 other locations · NCT06684379

• mRNA-1273 variant-containing COVID-19 vaccine: immune response and safety

  This will test variant-containing mRNA-1273 COVID-19 vaccine formulations to see if they boost immunity and are safe for previously vaccinated adults and selected children with risk factors.

  Recruiting at 6 sites Phase 4 ModernaTX, Inc. · Atlanta, Georgia and 5 other locations · NCT06585241

• Impact of Viral Infections on Blood Cell Development

  This study is trying to see how HIV and COVID-19 affect the development of blood cells in both healthy people and those with HIV by looking at their bone marrow.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt · NCT06458504

• Understanding how long COVID-19 can persist after recovery

  This study is trying to find out how long the COVID-19 virus can stick around in people who have recovered and how quickly their bodies make antibodies.

  Recruiting Columbia University · New York, New York · NCT04448145

• Understanding the immune response in COVID-19 patients in intensive care

  This study looks at how the immune system reacts in adults with severe COVID-19 who are in intensive care to help improve future treatments.

  Recruiting at 5 sites Hospices Civils de Lyon · Bron and 7 other locations · NCT04392401

NIH-funded research (newest 40 of 432)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• How COVID-19 infection and genes may influence memory and dementia risk

  This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11617103

• Understanding flu and COVID-19 vaccine responses in people and in the lab

  Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.

  NIH research Stanford University · Stanford, United States · NIH-11591264

• Oral small molecule inhibitors to block SARS-CoV-2 RNA replication

  A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.

  NIH research Stanford University · Stanford, United States · NIH-11587830

• Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses

  Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.

  NIH research Stanford University · Stanford, United States · NIH-11587807

• Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication

  A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.

  NIH research Scripps Research Institute, the · La Jolla, United States · NIH-11542055

• How different COVID-19 vaccines shape immune responses

  This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11481643

• How immune responses shape COVID-19's shift from outbreak to regular circulation

  This project looks at how different antibody and mucosal immune responses after infection or vaccination affect COVID-19 spread in people living in a crowded urban community.

  NIH research Yale University · New Haven, United States · NIH-11469885

• Alzheimer’s-related dementia after COVID-19: how SARS-CoV-2 affects the brain and potential drug repurposing

  This research looks at how COVID-19 may contribute to dementia by studying brain inflammation, blood vessel injury, and virus-host interactions, with the goal of finding existing drugs that could help.

  NIH research Cleveland Clinic Lerner Com-Cwru · Cleveland, United States · NIH-11457086

• IL-22’s role in SARS-CoV-2 infection and tissue protection

  A short study to understand how the cytokine IL-22 might help protect tissues during and after COVID-19 infection, especially in people with complications related to acute graft-versus-host disease.

  NIH research University of Oklahoma Hlth Sciences Ctr · Oklahoma City, United States · NIH-11451891

• SARS-CoV-2 replication machinery: how it works and how to block it

  A scientist team is studying how the coronavirus copies its RNA and how drugs like remdesivir stop it, with the goal of making better antivirals for patients.

  NIH research Rockefeller University · New York, United States · NIH-11449410

• SARS-CoV-2, social factors, and immune-driven depression risk

  Researchers are studying how COVID-19 infection and social conditions affect immune signals linked to depression, to see who might be most at risk.

  NIH research University of Texas at Austin · Austin, United States · NIH-11418062

• AT191: A self-administered RNA antiviral that fights SARS-CoV-2 across variants

  A new inhaled RNA-based antiviral (AT191) being developed to be used at home to help prevent hospitalizations and deaths from SARS-CoV-2 across its variants.

  NIH research Autonomous Therapeutics, INC. · Silver Spring, United States · NIH-11415109

• qPCR method to measure SARS-CoV-2-specific T cells in people with immune suppression

  A quick, blood test using qPCR to detect SARS-CoV-2–specific T cells in people with multiple myeloma and other immune weaknesses.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11413343

• Dual inhibitors targeting SARS-CoV-2 main protease and host cathepsin L as antivirals

  Researchers are developing a two-pronged antiviral treatment that blocks the virus’s main protein and a human enzyme to stop SARS-CoV-2 from replicating.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11411408

• A newer, smarter vaccine delivery system for COVID-19 vaccines

  This grant explores how lipid nanoparticles used in vaccines influence the immune response and how to design better vaccines for people.

  NIH research University of Vermont & St Agric College · Burlington, United States · NIH-11406290

• Maternal SARS-CoV-2 infection and its effects on placenta and child development

  This grant studies how COVID-19 infection during pregnancy might change the placenta and influence a child’s brain development, especially in kids who may be at higher genetic risk for ADHD/ASD.

  NIH research Lieber Institute, INC. · Baltimore, United States · NIH-11402254

• How COVID-19 and genetics influence memory and dementia risk in older adults

  This project studies how getting COVID-19 interacts with people’s genetic makeup to affect the likelihood of cognitive decline and Alzheimer’s disease in older adults from diverse backgrounds.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11401787

• How COVID-19 and other common respiratory viruses affect young children

  Looks at how having COVID-19 at the same time as other respiratory viruses changes illness and complications in infants and young children.

  NIH research Kaiser Foundation Research Institute · Oakland, UNITED STATES · NIH-11401570

• Understanding why some people keep SARS-CoV-2 infection longer and how to stop it

  Researchers are studying why immunocompromised people can have ongoing SARS-CoV-2 infections and how this persistence is linked to changes in the virus.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11401471

• Computational analysis of transcriptome rearrangements in SARS-CoV-2

  A computer-based project from Rutgers-Camden will look at how the coronavirus may rearrange its RNA to create new proteins, which could inform future drugs and vaccines.

  NIH research Rutgers the State Univ of Nj Camden · Camden, United States · NIH-11400974

• Understanding how SARS-CoV-2 triggers dangerous lung inflammation

  This grant studies how COVID-19 causes deadly lung inflammation by uncovering how infected airway cells and immune cells communication lead to a harmful inflammatory spike.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11400035

• Understanding how SARS-CoV-2 infection may worsen mold infections in the lungs

  This grant studies why severe COVID-19 can lead to dangerous lung mold infections, with the goal of improving prevention and care for patients affected by CAPA.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11399698

• How our immune system keeps a memory of vaccines and infections over time

  A long-term study to understand how T cells remember SARS-CoV-2 vaccines and infections, and how this compares with common cold coronaviruses.

  NIH research La Jolla Institute for Immunology · La Jolla, United States · NIH-11398855

• SARS-CoV-2 protease inhibitors to treat COVID-19

  Researchers at Purdue University are developing new drug compounds that block key SARS-CoV-2 proteases to help treat COVID-19.

  NIH research Purdue University · West Lafayette, United States · NIH-11397320

• Stable mRNA vaccine for new SARS-CoV-2 variants using RNA-plex protection

  A new approach aims to make mRNA vaccines against evolving COVID-19 variants more stable so they can be stored and distributed more easily.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11395650

• Longitudinal study of COVID-19 vaccine immunity in children and breast milk

  This study looks at how COVID-19 mRNA vaccines affect kids, their mothers, and breastfed babies over time.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11392364

• Impact of COVID-19 on latent TB reactivation in Kenya

  This project in Kenya checks how having had COVID-19 might influence the reactivation of latent tuberculosis in adults.

  NIH research Mount Kenya University · Thika, Kenya · NIH-11392293

• Discovery of SARS-CoV-2 antivirals using a replicon assay

  Researchers are developing new antiviral drugs against SARS-CoV-2 using a high-throughput replicon system to screen compounds in a safe, non-infectious setup.

  NIH research Emory University · Atlanta, United States · NIH-11391021

• How COVID-19 and genetic differences may affect memory and Alzheimer's risk across diverse populations

  This project will find out whether having COVID-19 together with certain genetic differences raises the chance of memory loss and Alzheimer's disease in older adults from varied ancestral backgrounds.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11389642

• How COVID-19 and genes may affect memory and Alzheimer's risk in diverse communities

  This project looks at whether COVID-19 infection together with genetic differences raises the chance of memory loss and Alzheimer's disease in older adults from diverse ancestries.

  NIH research University of Texas Hlth Science Center · San Antonio, United States · NIH-11389638

• Burden and consequences of influenza, SARS-CoV-2 and other respiratory viruses among Indian adults

  This grant aims to study how flu and COVID-19 and related respiratory infections affect Indian adults 18–60, including costs, outcomes, and vaccine uptake to inform health policy.

  NIH research All-India Institute of Medical Sciences · New Delhi, India · NIH-11388782

• Understanding how SARS-CoV-2 builds its outer shell and buds off

  This project studies how the coronavirus SARS-CoV-2 assembles its protective envelope and leaves the cell, with the goal of identifying new ways to block the virus.

  NIH research Purdue University · West Lafayette, United States · NIH-11386522

• SARS-CoV-2 immune responses in lymphoma patients

  This grant studies how people with lymphoma respond to COVID-19 vaccines and infection, aiming to understand why antibody and T cell responses can be weaker in NHL/CLL patients.

  NIH research Emory University · Atlanta, United States · NIH-11384773

• Emerging mechanisms of how coronaviruses interact with host cells to fight infection

  Scientists are studying how SARS-CoV-2 and related coronaviruses work with our bodies to spread and how to block them with new antiviral drugs.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11384445

• Role of AnnexinA2 in HIV-1 and SARS-CoV-2 virus assembly

  Scientists are studying how a protein called AnnexinA2 helps HIV-1 and SARS-CoV-2 viruses assemble inside cells, which could point to new ways to block these infections.

  NIH research California State University Long Beach · Long Beach, United States · NIH-11384149

• Leptin and fat cells: how obesity may worsen lung infections like COVID-19 and flu

  A study explores how fat tissue and the leptin pathway might change the body's first lung defenses during respiratory infections in people who are obese or have diabetes.

  NIH research Louisiana State Univ A&m Col Baton Rouge · Baton Rouge, United States · NIH-11382855

• PhAI-CoV: AI predicts SARS-CoV-2 variant evolution in people living with HIV

  A project uses smart computer models to forecast how SARS-CoV-2 might evolve in people with HIV, helping clinicians and patients stay ahead of dangerous variants.

  NIH research University of Florida · Gainesville, United States · NIH-11382774

• Blood DNA markings linked to long COVID symptoms

  This project looks at how patterns of DNA methylation in blood relate to long-term COVID-19 effects in patients who were seriously ill.

  NIH research Albany Medical College · Albany, United States · NIH-11381710

• Peptide blockers to stop COVID-19 spread

  Researchers are developing lipid‑attached peptide antivirals meant to stop SARS‑CoV‑2 from entering cells and reduce person‑to‑person spread.

  NIH research Columbia University Health Sciences · New York, United States · NIH-11380521

• Vaccine effectiveness in preventing respiratory illness in Washington state (2022–2027)

  This project tests how well vaccines against flu, COVID-19, and other respiratory viruses protect people in Washington state from getting acutely ill.

  NIH research Kaiser Foundation Health Plan of Washington · Seattle, United States · NIH-11379693

Related topics

Quick answers

How many SARS-CoV-2 clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 11 countries. The most sites are in United States (6 trials), France (2 trials), Spain (1 trial), Bulgaria (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 2, Phase 1/2: 1, Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →